MARKET

RXRX

RXRX

Recursion Pharmaceuticals, Inc.
NASDAQ
5.59
+0.23
+4.29%
After Hours: 5.63 +0.04 +0.72% 16:44 07/09 EDT
OPEN
5.46
PREV CLOSE
5.36
HIGH
5.77
LOW
5.43
VOLUME
34.08M
TURNOVER
--
52 WEEK HIGH
12.36
52 WEEK LOW
3.790
MARKET CAP
2.27B
P/E (TTM)
-3.1470
1D
5D
1M
3M
1Y
5Y
1D
Nvidia hits $4T market cap, Merck acquires Verona Pharma: Morning Buzz
TipRanks · 13h ago
Recursion Pharmaceuticals: The AI Drug Discovery Play
NASDAQ · 1d ago
Recursion Pharmaceuticals call volume above normal and directionally bullish
TipRanks · 1d ago
Here's Why Shares in Recursion Pharmaceuticals Surged Today
The Motley Fool · 1d ago
Recursion Pharmaceuticals Stock Gains on Plans to Buy Drug-Development Interest from Rallybio
Dow Jones · 1d ago
Recursion Pharmaceuticals Price Target Maintained With a $8.00/Share by Needham
Dow Jones · 1d ago
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target
Benzinga · 1d ago
Microchip Technology, Tesla, Humacyte And Other Big Stocks Moving Higher On Tuesday
Benzinga · 1d ago
More
About RXRX
Recursion Pharmaceuticals, Inc. is a clinical stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology include REC-617, REC-1245, REC-3565 and REC-4539. Its clinical programs in rare diseases include REC-994, REC-4881, REC-2282, and REC-3964. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors.

Webull offers Recursion Pharmaceuticals Inc stock information, including NASDAQ: RXRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RXRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RXRX stock methods without spending real money on the virtual paper trading platform.